BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 08, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 11/5 cls
Avanir Pharmaceuticals Inc. Canaccord Ritu Baral Price target Buy 98% $4.79
(NASDAQ:AVNR) Jefferies Andrew Fein Price target Buy
Baral raised her target to $10 from $9 after FDA approved an NDA from Avanir for Nuedexta dextromethorphan/quinidine to treat pseudobulbar affect (PBA). Avanir plans to launch the drug next quarter. Baral noted the product was approved without a REMS or black box warning. Nuedexta is a combination of the NMDA receptor antagonist dextromethorphan with quinidine sulfate, a cytochrome P450 2D6 enzyme inhibitor (see BioCentury, Nov. 1).
Fein raised his target to $15 from $10 on the Nuedexta news.
Biodel Inc. (NASDAQ:BIOD) Leerink Joshua Schimmer Price target Market perform -48% $1.88
Wedbush Liana Moussatos Price target Market outperform
Schimmer lowered his target to $2 from $5-6 after FDA issued a complete response letter and requested two new clinical trials for diabetes candidate Linjeta (formerly VIAject). He removed Linjeta from his model due to the lack of clarity on a partnership or financial potential. Biodel had submitted...

Read the full 1258 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >